Argus Lifts Pfizer Target to $40 as Pipeline Wins Meet a Muted Market
Published on 11/08/2026 at 05:52 | Editorial boerse-global.de
Argus raised its price target on Pfizer from $35 to $40 on Wednesday while reaffirming its buy rating, citing the drugmaker's improved revenue and earnings outlook. The move puts a sharper question in front of investors: does the brighter financial picture justify fresh confidence, or should they wait for more concrete progress from the medicines business first?
The stock's reception has been cool. Shares slipped 1.1% on Friday to close at €26.34, with media coverage pointing to softer sales of COVID products as the drag. That tepid reaction sits alongside the raised guidance Pfizer issued just over a week ago — a forecast that now serves as the yardstick for coming quarterly reports.
Third-Quarter Base and Full-Year Targets
Pfizer reported third-quarter 2026 revenue of $16.6 billion on Tuesday, with adjusted diluted earnings per share of $0.87. Those figures form the financial starting point against which the pipeline story will be measured.
For the full year 2026, the company expects revenue of $62.0 billion to $64.0 billion and adjusted diluted EPS of $2.95 to $3.05. Hitting those numbers with the existing business — and backing them up with progress in the drug portfolio — is what matters from here, and oncology offers a concrete test given that both clinical and regulatory advances are already in hand.
Two Cancer Assets, Two Different Stages
Pfizer said on October 27 that ELREXFIO met the primary endpoint on progression-free survival in the Phase 3 MagnetisMM-32 trial, which enrolled patients with relapsed or refractory multiple myeloma. The company plans to submit the data to regulators worldwide. The upside case rests on those filings going ahead and translating into regulatory decisions that could improve the drug's commercial prospects.
Should investors sell immediately? Or is it worth buying Pfizer?
TALZENNA is further along. The FDA on October 26 approved it in combination with XTANDI for an earlier treatment setting in metastatic prostate cancer, covering adults with certain HRR gene mutations. That opens an additional option within a clearly defined patient group — value that depends on how successfully Pfizer commercializes the expanded label.
A New Finance Chief and a Vaccine Readout
Alongside the quarterly numbers, Pfizer named Cecile Guegan as chief financial officer effective November 1, disclosing the decision Tuesday in a mandatory filing with the US Securities and Exchange Commission. Guegan had run the finance function on an interim basis since August 16 and also takes the title of Executive Vice President.
On the research side, Pfizer presented Phase 2 data on October 24 at IDWeek 2026 for its pediatric pneumococcal conjugate vaccine candidate. A four-dose series generated immune responses against all 25 serotypes, and safety and tolerability were comparable to PREVNAR 20, according to the company.
Execution Is the Swing Factor
The main risk is delivery. The financial forecast describes the expected full-year business, while the future contribution of the cancer drugs hinges on developments still to come. Investors would be taking on more risk by pricing potential additional revenue fully into their valuations today.
Manufacturing restructuring adds another variable. Fierce Pharma reported on October 22 that Pfizer is cutting jobs at US production sites; the company confirmed workforce reductions in manufacturing but did not verify the individual locations or headcount figures in the report. If efficiency gains come without disrupting operations, the restructuring could support earnings — if execution suffers, it would blunt the benefit of the higher expectations.
What to Watch Next
As long as Pfizer meets its raised annual targets and keeps advancing in oncology, a more favorable business trajectory remains a plausible scenario. A stumble in execution would turn the loftier expectations into a valuation risk instead. The benchmark is therefore the combination of financial delivery and verifiable drug-pipeline progress.
The clearest near-term catalyst is the planned submission of the ELREXFIO data to regulators, which would convert the clinical win into the next scheduled development step. For TALZENNA, attention shifts to how well the expanded approval is turned into commercial traction. The case for the shares is a conditional one: the opportunity gains weight if Pfizer builds further business momentum from the milestones already reached, while missing the raised bar would push the valuation back toward what the business has actually delivered.
Ad
Pfizer Stock: New Analysis - 8 November
Fresh Pfizer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
